contact us jpkrencn

事業内容

Medicilon Preclinical Research for Cellular Immunotherapies

あなたはここにいる:ホーム > 事業内容 > Integrated Projects > Medicilon Preclinic...

Medicilon has built a one-stop research platform for the preclinical R&D of cellular immunotherapies, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK. Using a wealth of animal models and a variety of advanced analysis techniques, comprehensively considering the characteristics of different research projects, Medicilon has completed numerous pre-clinical projects for clients worldwide.

Cellular immunotherapy has developed by leaps and bounds in recent years, providing a cure for many difficult-to-treat cancers. With the continuous discovery of tumor targets and mechanisms, the track is still full of vitality and hope bringing new breakthroughs in tumor treatment and human welfare.

Medicilon has built a one-stop research platform for the preclinical R&D of cellular immunotherapies, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK. Using a wealth of animal models and a variety of advanced analysis techniques, comprehensively considering the characteristics of different research projects, Medicilon has completed numerous pre-clinical projects for clients worldwide.

Introduction to the Test Product

类别 CAR-T Cell TCR-T Cell CAR-NK Cell
DNT Cell TIL Cell

The complexity of Immune Cells:

  • · Proliferation in vivo
  • · Limited batches and production
  • · Raw materials with huge variations
  • · Individualization and heterogeneity
  • · Complicated preparation process

Introduction to Non-Clinical Research Services

In vitro Pharmacodynamic Studies

  • · Tumor killing rate or proliferation inhibition rate
  • · Expression of IFN-γ
  • · Phenotypic changes of immune cells

In vivo Pharmacodynamic Research

Technical Method
  • · Bioluminescence Imaging Technology
  • · Flow Cytometry
  • · Immunoassay Technology
  • · Pathology Technology
Model Resources
  • · Homologous Mouse Model
  • · Transgenic Mouse Model
  • · Transplanted Tumor Mouse Model
  • A target

    B target

    A target & B target

    The picture shows the pharmacodynamic study of dual-target CAR-T cells in K 562 subcutaneously transplanted tumor mouse model

  • · Humanized Mouse Model of Immune System Reconstruction
  • The picture shows the pharmacodynamic study of the mouse pharmacodynamic model of hPBMC immune system reconstruction induced by Raji-luc fluorescein-labeled lymphoma cells

Pharmacokinetic research

The parmacokinetc research studies sample in vivo behaviors, such as distribution, proliferation and survival time. We also track transgenic product expressed and secreted outside the immune cells, if any, to provide its local and/or systemic exposure characteristics.

Technology Platform
  • · Imaging Technology
  • · Flow Cytometry
  • · Immunohistochemistry Technology
  • · Quantitative PCR Technology
  • · ddPCR
  • · ELISPot

Non-clinical Safety Studies

The non-clinical safety studies of cellular immunotherapies are mainly designed and carried out based on the potential safety risks of the drugs. In addition to the common safety risks, cell therapies may also contain the risks of:

  • · Cytokine Release Syndrome (CRS)
  • · Graft Versus Host Disease (GVHD)
  • · Reversible Neurotoxicity
  • · B Cell Reduction
  • · On-Target / Off-Tumor
  • · Tumorigenic / Tumorigenic
Model Resources:
  • · Homologous Mouse Model
  • · Transgenic Mouse Model
  • · Transplanted Tumor Mouse Model
  • · Non-Tumor-Bearing Immunodeficiency Mice
  • · HIS Mouse Model
  • · Various methods of administration such as intravenous injection, intratumoral injection, and joint cavity injection are available.
Model Resources:
  • · Homologous Mouse Model
  • · Evaluation Content
  • · Single Dose Toxicity Test
  • · Repeated Dose Toxicity Test
  • · Immunogenicity / Immunotoxicity
  • · In vitro Soft Agar Clone Growth Test
  • · In vivo Tumorigenicity / Tumorigenicity
  • · Formulation Safety
  • · Other: Express Product Safety

関連研究室